Literature DB >> 3347355

Unusual presentation of cis-platinum neuropathy.

J E Mollman1, W M Hogan, D J Glover, L F McCluskey.   

Abstract

Symptoms and signs of cis-diamminedichloroplatinum II (DDP) neuropathy usually develop during treatment and stabilize or improve when DDP is stopped. We report three patients whose symptoms began 3 to 8 weeks after the last dose of DDP and progressed over 1 or 2 months to moderate-marked disability. The clinical picture in each was consistent with DDP neuropathy, and no other cause could be identified. Two of the patients improved over 8 and 27 months to become asymptomatic; the other died 2 months after presentation. It is important to recognize that DDP neuropathy can present after treatment has been discontinued since the clinical picture mimics the paraneoplastic dorsal root ganglionitis, which has a different prognosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3347355     DOI: 10.1212/wnl.38.3.488

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.

Authors:  A Hovestadt; M E van der Burg; H B Verbiest; W L van Putten; C J Vecht
Journal:  J Neurol       Date:  1992-03       Impact factor: 4.849

2.  Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement.

Authors:  W Boogerd; W W ten Bokkel Huinink; O Dalesio; W J Hoppenbrouwers; J J van der Sande
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

Review 3.  Chemotherapy-induced peripheral neuropathies in hematological malignancies.

Authors:  Joost Louis Marie Jongen; Annemiek Broijl; Pieter Sonneveld
Journal:  J Neurooncol       Date:  2014-10-19       Impact factor: 4.130

4.  Progressive paresthesias after cessation of therapy with very high-dose cisplatin.

Authors:  S M Grunberg; S Sonka; L L Stevenson; F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Accumulation of platinum in the intervertebral discs and vertebrae of ovarian tumor-bearing patients treated with cisplatin.

Authors:  T Minami; K Hashii; I Tateyama; E Kadota; Y Tohno; S Tohno; M Utsumi; M O Yamada; M Ichii; K Namikawa
Journal:  Biol Trace Elem Res       Date:  1994-09       Impact factor: 3.738

6.  Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle.

Authors:  J S Gill; A J Windebank
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

7.  Cisplatin neuropathy: clinical course and neurophysiological findings.

Authors:  M LoMonaco; M Milone; A P Batocchi; L Padua; D Restuccia; P Tonali
Journal:  J Neurol       Date:  1992-04       Impact factor: 4.849

Review 8.  Antibodies and neuronal autoimmune disorders of the CNS.

Authors:  Francesc Graus; Albert Saiz; Josep Dalmau
Journal:  J Neurol       Date:  2009-12-25       Impact factor: 4.849

9.  Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.

Authors:  Krzysztof Brzeziński
Journal:  Contemp Oncol (Pozn)       Date:  2012-02-29

10.  Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis.

Authors:  M von Schlippe; C J Fowler; S J Harland
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.